CA-GLIDE
14.5.2018 15:02:08 CEST | Business Wire | Press release
GLIDE is pleased to announce the 19th Annual eBay for Charity Auction for Power Lunch with Warren Buffett . Offered through eBay for Charity , bidding for this year’s auction begins at 7:30 pm PDT on Sunday, May 27 and ends at 7:30 pm PDT Friday, June 1. Bidding starts at $25,000 and all bidders must pre-qualify at eBay.com/GLIDE . The winning bidder and up to seven friends will have the opportunity to dine with Mr. Buffett at Smith & Wollensky in New York City.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180514005268/en/
For over 50 years, GLIDE has stood with the most vulnerable, including the poor and marginalized, those challenged by illness, homelessness, hunger, discrimination and exclusion. GLIDE remains a place for all in need to find a warm meal, access to healthcare and shelter, childcare and family services, and someone to advocate for them. GLIDE serves roughly 750,000 free meals a year.
“GLIDE really takes people who have hit rock bottom and helps bring them back, said Warren Buffett . “They've been doing it for decades. If I can help out by raising some money for them, then I enjoy doing it.”
“We are grateful to Warren Buffett and eBay for enabling us to reach thousands with our programs and support,” said GLIDE’s Co-Founder Reverend Cecil Williams .
“Warren Buffett’s generosity provides direct support to help the disenfranchised transform their lives. It allows GLIDE to remain a driving force for racial and economic equity in San Francisco and beyond,” said GLIDE President and CEO Karen Hanrahan .
“eBay is honored to continue our partnership with GLIDE for this iconic auction and help in its mission of alleviating the suffering of those under the debilitating grasp of poverty,” said eBay’s President and CEO Devin Wenig . “eBay’s community embodies the steadfast dedication to our goal of raising a billion dollars for charities by 2020.”
Over the past 18 years, the winning bids have ranged from $25,000 (prior to eBay’s involvement) to $3,456,789. Funds raised go directly to support GLIDE’s programs. eBay will host the auction for the 16th year in a row.
For more information, please contact GLIDE at 415-674-6060 , Buffett@GLIDE.org or visit eBay.com/GLIDE .
View source version on businesswire.com: https://www.businesswire.com/news/home/20180514005268/en/
Contact:
for GLIDE
Denise Lamott, 415-381-8793
Denise@DeniseLamottPR.com
or
Kari
Ramirez, 408-219-5120
Press@ebay.com
Link:
Social Media:
https://www.facebook.com/eBayforCharityUS/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom